BKM120 + Trastuzumab + Paclitaxel + BKM120 Placebo
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-positive Newly Diagnosed, Primary Breast Cancer
Conditions
HER2-positive Newly Diagnosed, Primary Breast Cancer
Trial Timeline
Sep 3, 2013 → Feb 18, 2015
NCT ID
NCT01816594About BKM120 + Trastuzumab + Paclitaxel + BKM120 Placebo
BKM120 + Trastuzumab + Paclitaxel + BKM120 Placebo is a phase 2 stage product being developed by Novartis for HER2-positive Newly Diagnosed, Primary Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01816594. Target conditions include HER2-positive Newly Diagnosed, Primary Breast Cancer.
What happened to similar drugs?
0 of 15 similar drugs in HER2-positive Newly Diagnosed, Primary Breast Cancer were approved
Approved (0) Terminated (0) Active (15)
🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
🔄SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01816594 | Phase 2 | Completed |
Competing Products
20 competing products in HER2-positive Newly Diagnosed, Primary Breast Cancer